Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms

  Placebo ER guaifenesin Overall
  (n = 190) (n = 188) (N = 378)
Mean age, years ± SD 40.8 ± 15.04 41.1 ± 13.91 41.0 ± 14.47
Age range, years 13 – 83 18 – 85 13 – 85
Sex, male % 55.8 48.9 52.4
Sex, female % 44.2 51.1 47.6
Race, White % 61.1 60.6 60.8
Black % 33.2 36.7 34.9
Asian % 4.2 1.6 2.9
American Indian or Alaska Native % 1.6 0.5 1.1
Other % 0 0.5 0.3
Ethnicity, Hispanic or Latino % 5.3 7.4 6.3
Not Hispanic or Latino % 94.7 92.6 93.7
Onset day of cold symptoms before study entry    
−8 days % 0.5 0 0.3
−6 days % 0.5 0 0.3
−5 days % 3.7 5.3 4.5
−4 days % 26.8 19.7 23.3
−3 days % 39.5 38.3 38.9
−2 days % 21.1 32.4 26.7
−1 days % 7.4 4.3 5.8
0 days % 0.5 0 0.3
Onset day of productive cough before study entry    
−7 days % 0.5 0 0.3
−5 days % 0 0.5 0.3
−4 days % 2.6 1.1 1.9
−3 days % 14.7 10.1 12.4
−2 days % 46.3 50.5 48.4
−1 days % 31.1 34.0 32.5
0 days % 4.7 3.7 4.2
Diagnosis before study entry    
Acute nasopharyngitis/rhinopharyngitis % 81.6 83.0 82.3
Acute bronchitis % 10.0 6.9 8.5
Acute sinusitis % 4.7 6.9 5.8
Acute pharyngitis % 2.6 2.1 2.4
Acute laryngitis % 0.5 0.5 0.5
Other % 0.5 0.5 0.5
  1. SD: standard deviation. Note: Onset day is relative to first dose date and all percentages are based on the number of patients in each treatment group.